ANNOUNCEMENT

1. 22 October 2009 

[read more]

Researches

SERVICES

Oncology Services

1. Xenograft model

2. In vivo target inhibition model

EMAN provides state-of-the-art preclinical xenograft models with multiple cell lines to support preclinical research and assessment of anticancer drugs. Our expert scientific staffs possess strong technical and academic backgrounds. With our new and complete laboratory facilities, validated xenograft models and supporting studies, EMAN is able to support a complete discovery and development program for anti-cancer drugs. We have established multiple in vitro and in vivo assay systems to evaluate novel anti-cancer compounds. Each assay is designed to understand specific aspects of drug property and its mechanism of action. By accessing our comprehensive capability, our customers can advance development programs in a timely and cost-effective manner. EMAN scientists have extensive experience with the design and execution of efficacy studies for all types of experimental cancer therapeutic agents including both small molecules and biologics. Our current cancer pharmacology service portfolio includes:

Human Xenograft Model

Human xenograft models are generated by inoculating a tumour cell lines into an immunodeficient rodent such as nude mice. This is a subcutaneous xenograft models. This model involves implantation of tumour cells via subcutaneous injection into the flank of nude mice. This model provides consistent and reproducible cell growth and permits easy access to the tumour for treatment and calliper measurement. We offer traditional subcutaneous models and other models and can customize models to meet a sponsor’s needs.

Human Tumour Cell lines available at EMAN are as follows-

Typical Study Parameters we evaluate at EMAN:

1. Human tumour cells grown in culture (ATCC or custom lines)

2. Cell implant subcutaneously into immuno-compromised animals

3. Tumours measured during growth phase

4. Animals treated with vehicle, test article, and positive controls

5. Various protocol-specified parameters/markers assessed ex vivo or in vivo assays

6. Report preparation.

EMAN scientific teams not only investigate the effect of test article on tumour growth but also actively participate in investigating the mode of action. In PK/PD studies the tumours are excised from the test article treated mice group along with respective control groups. Then the effect of test article at molecular level is investigated in different cell based assays. The MTD of the compound is also analysed.

EMAN follows the ASTM Testing Methods

ASTM F813 Direct Contact Cell Culture Evaluation of Materials for Medical Devices

TEAM MEMBERS

Principal Investigator:

Dr. Amin Malik Shah Bin Abdul Majid








PhDs:




Masters:

Zena A. Abdul Hameed

Norshirin binti Idris

Nozlena binti Abdul Samad

Muath Hekmat Helal

FACILITIES

CONTACT US

 Dr. Amin Malik Shah bin Abdul Majid
School of Pharmaceutical Sciences, Universiti Sains Malaysia
Minden, 11800 Penang, Malaysia
Tel: 604-6577888 Ext. 4582
Email: : aminmalikshah@usm.my
Fax: 604-6570017

COLLABORATIONS

under contrastruction.

PUBLICATIONS

2009

1. H.B., Sahib, A.F. Aisha, M.F. Yam, M.Z. Asmawi and Z. Ismail et al., 2009. Anti-angiogenic and anti oxidant properties of Orthosiphon stamineus benth. Methanolic leaves extract. Int. J. Pharmacol., 5: 162-167.
   

2. Sahib, H.B., Z. Ismail, N.H. Othman and A.M.S. Abdul Majid, 2009. Orthosiphon stamineus benth. methanolic extract enhances the anti-proliferative effects of tamoxifen on human hormone dependent breast cancer. Int. J. Pharmacol., 5: 273-276.
   

3. Aisha, A.F.A., Sahib, H.B., K.M. Abu-Salah, Y. Darwis and A.M.S. Abdul Majid, 2009.Cytotoxic and anti-angiogenic properties of the stem bark extract of sandoricum koetjap. Int. J. Cancer Res.( In Press)
   

4. A.F.A. Aisha, S.A. Alrokayan, K.M. Abu-Salah, Y. Darwis and A.M.S. Abdul Majid, 2009. In vitro Cytotoxic and Apoptotic Properties of the Stem Bark Extract of Sandoricum koetjape on Breast Cancer Cells, Int. J. Cancer Res.( In Press)
   
   

ABOUT EMAN

EMAN Research Laboratory is located in the School of Pharmaceutical Sciences, University Science Malaysia on the island of Penang.

EMAN focuses on early discovery of compounds that have potential anti-cancer activity and agents that perturb the angiogenesis pathways. The latter has wide variety of disease application including rheumatoid arthritis, diabetic blindness; age related macular degeneration, obesity, Alzheimer and cancer.

 EMAN provides testing services for in vitro and in vivo tumor and angiogenesis model as a proof of concept for test compound pharmacological activity validation. The testing facility includes a 2000 sq ft state-of-the are clean room facility that improves the quality of the testing services.

EMAN aims to provide its services to the local industries in Malaysia to facilitate the development of new drugs. EMAN also provides in vitro testing services for cytotoxic testing and mutagenicity testing according to ASTM methods.

TEAM MEMBERS

THE BIG BOSS


THE SECERTARY


DOCTORATES




MASTERS